hVIVO was notified by Octopus Investments Ltd on 13th September 2024 that it has increased its shareholding to 61,801,224 shares (9.08%) up from 8% previously.
Continue readinghVIVO was notified by Rathbones Investment Management Ltd on September 5th that it has 34,096,062 shares (5.011400%)
Continue readinghVIVO #HVO – Major Shareholding Notification TR1 hVIVO was notified by Octopus Investments on August 6th that it has increased its shareholding to 54,438,725 shares (8%) up from 7.61% previously
Continue readinghVIVO #HVO – Major Shareholding Notification TR1 hVIVO was notified by Octopus Investments that it has increased its shareholding to 51,804,020 shares (7.61%) up from 4.4% previously
Continue readinghVIVO plc (AIM & Euronext: HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has been notified that Cathal Friel, Chairman, sold 21,159,177 ordinary shares in the Company earlier today at 29p each to satisfy institutional demand post the Company’s recent capital markets event. The shares sold were held through Raglan Road Capital Limited, a company owned and controlled by Cathal…
Continue readinghVIVO #HVO – Major Shareholding Notification TR1 hVIVO was notified by Octopus Investments that it has increased its shareholding to 30,054,020 shares (4.42%) up from 3.1% previously
Continue readinghVIVO plc (AIM & Euronext: HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, provides a trading update for the six-month period ended 30 June 2024. Highlights • Revenue of £35.6 million, 30.6% higher than H1 2023 (£27.3 million). The Board remains confident in delivering on market expectations for the full year • EBITDA margin of c.24% (H1 2023: 19.1%) •…
Continue readinghVIVO plc (AIM & Euronext: HVO), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that all resolutions put to shareholders at the Company’s Annual General Meeting held earlier today were duly passed. For further information please contact: hVIVO plc +44 (0) 20 7756 1300 Yamin ‘Mo’ Khan, Chief Executive Officer Stephen Pinkerton, Chief Financial Officer Cavendish Capital Markets…
Continue readingA record year across all financial and operational metrics On track to deliver future growth targets Initiating annual dividend policy hVIVO plc (AIM & Euronext: HVO), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces its audited results for the year ended 31 December 2023. Financial highlights • Revenue up 16% to £56.0 million (2022: £48.5 million) • EBITDA up…
Continue readingTRI: JP Morgan Asset Management UK Ltd now hold 34,347,989 shares (5.048410%) indirect voting rights and 12,710,689 shares (1.868195%) and as a result hold a combined 47,058,678 shares (6.916605%) of the company
Continue reading
